• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

寻找阿尔茨海默病的治疗方法。

The Quest for an Alzheimer Therapy.

作者信息

Cappa Stefano F

机构信息

Institute for Advanced Studies (IUSS), Pavia, Italy.

IRCCS S. Giovanni di Dio Fatebenefratelli, Brescia, Italy.

出版信息

Front Neurol. 2018 Mar 1;9:108. doi: 10.3389/fneur.2018.00108. eCollection 2018.

DOI:10.3389/fneur.2018.00108
PMID:29599741
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5863504/
Abstract

This mini-review considers three different approaches to the therapy and prevention of Alzheimer's disease (AD): replacement therapy, disease modification, and multi-level interventions. Each of these research frameworks has direct implications at the clinical level, leading to an emphasis on different time points of the AD continuum. While all perspectives continue to play an important role in current efforts to reach the ambitious target of an effective therapy or prevention of AD by 2025, it is clear that novel paradigms are needed, including new models of clinical trial design. This goal can only be accomplished by a concerted effort of academia, governmental agencies, and industry.

摘要

本综述探讨了治疗和预防阿尔茨海默病(AD)的三种不同方法:替代疗法、疾病修饰疗法和多层次干预。这些研究框架中的每一种在临床层面都有直接影响,导致对AD病程不同时间点的重视。虽然所有观点在当前为实现到2025年有效治疗或预防AD这一宏伟目标所做的努力中仍发挥着重要作用,但显然需要新的范式,包括新的临床试验设计模式。这一目标只能通过学术界、政府机构和行业的共同努力来实现。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/239c/5863504/eb2aa6d2360e/fneur-09-00108-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/239c/5863504/eb2aa6d2360e/fneur-09-00108-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/239c/5863504/eb2aa6d2360e/fneur-09-00108-g001.jpg

相似文献

1
The Quest for an Alzheimer Therapy.寻找阿尔茨海默病的治疗方法。
Front Neurol. 2018 Mar 1;9:108. doi: 10.3389/fneur.2018.00108. eCollection 2018.
2
[The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].[美国国立衰老研究所和阿尔茨海默病协会关于阿尔茨海默病诊断指南的2011年新建议:临床前阶段、轻度认知障碍和痴呆症]
Rev Neurol (Paris). 2012 Jun;168(6-7):471-82. doi: 10.1016/j.neurol.2011.11.007. Epub 2012 May 12.
3
Topical Discoveries on Multi-Target Approach to Manage Alzheimer's Disease.阿尔茨海默病多靶点治疗方法的局部发现
Curr Drug Metab. 2018;19(8):704-713. doi: 10.2174/1389200219666180305152553.
4
Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.阿尔茨海默病患者脑脊液中的β-淀粉样蛋白(1-42):早发型与晚发型阿尔茨海默病的差异及疾病过程中的稳定性
Arch Neurol. 1999 Jun;56(6):673-80. doi: 10.1001/archneur.56.6.673.
5
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.NIA-AA 研究框架:迈向阿尔茨海默病的生物学定义。
Alzheimers Dement. 2018 Apr;14(4):535-562. doi: 10.1016/j.jalz.2018.02.018.
6
Clinical Research on Alzheimer's Disease: Progress and Perspectives.阿尔茨海默病的临床研究:进展与展望。
Neurosci Bull. 2018 Dec;34(6):1111-1118. doi: 10.1007/s12264-018-0249-z. Epub 2018 Jun 28.
7
Alzheimer's disease.阿尔茨海默病
Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14.
8
Prevention trials in Alzheimer's disease: an EU-US task force report.阿尔茨海默病预防试验:欧盟-美国特别工作组报告。
Prog Neurobiol. 2011 Dec;95(4):594-600. doi: 10.1016/j.pneurobio.2011.08.014. Epub 2011 Sep 10.
9
10
Prevention of Alzheimer's disease: a global challenge for next generation neuroscientists.阿尔茨海默病的预防:下一代神经科学家面临的全球挑战。
J Alzheimers Dis. 2014;42 Suppl 4:S515-23. doi: 10.3233/JAD-141479.

引用本文的文献

1
Beyond Transgenic Mice: Emerging Models and Translational Strategies in Alzheimer's Disease.超越转基因小鼠:阿尔茨海默病的新兴模型与转化策略
Int J Mol Sci. 2025 Jun 10;26(12):5541. doi: 10.3390/ijms26125541.
2
Protective Effects of Bifidobacterium Breve MCC1274 as a Novel Therapy for Alzheimer's Disease.短双歧杆菌MCC1274作为阿尔茨海默病新疗法的保护作用
Nutrients. 2025 Jan 31;17(3):558. doi: 10.3390/nu17030558.
3
Ribonucleotide reductase inhibition improves the symptoms of a Caenorhabditis elegans model of Alzheimer's disease.

本文引用的文献

1
Alzheimer's disease drug development pipeline: 2017.2017年阿尔茨海默病药物研发进展
Alzheimers Dement (N Y). 2017 May 24;3(3):367-384. doi: 10.1016/j.trci.2017.05.002. eCollection 2017 Sep.
2
Dementia prevention, intervention, and care.痴呆症的预防、干预与护理。
Lancet. 2017 Dec 16;390(10113):2673-2734. doi: 10.1016/S0140-6736(17)31363-6. Epub 2017 Jul 20.
3
Clinical validity of delayed recall tests as a gateway biomarker for Alzheimer's disease in the context of a structured 5-phase development framework.
核苷酸还原酶抑制可改善阿尔茨海默病秀丽隐杆线虫模型的症状。
G3 (Bethesda). 2024 May 7;14(5). doi: 10.1093/g3journal/jkae040.
4
The role of Alzheimer's disease risk genes in endolysosomal pathways.阿尔茨海默病风险基因在溶酶体途径中的作用。
Neurobiol Dis. 2022 Jan;162:105576. doi: 10.1016/j.nbd.2021.105576. Epub 2021 Dec 3.
5
ApoE-Targeting Increases the Transfer of Solid Lipid Nanoparticles with Donepezil Cargo across a Culture Model of the Blood-Brain Barrier.靶向载脂蛋白E可增加载有多奈哌齐的固体脂质纳米粒透过血脑屏障培养模型的转运。
Pharmaceutics. 2020 Dec 29;13(1):38. doi: 10.3390/pharmaceutics13010038.
6
Antifungal drug miconazole ameliorated memory deficits in a mouse model of LPS-induced memory loss through targeting iNOS.抗真菌药物咪康唑通过靶向 iNOS 改善 LPS 诱导的记忆缺失小鼠模型的记忆缺陷。
Cell Death Dis. 2020 Aug 14;11(8):623. doi: 10.1038/s41419-020-2619-5.
7
A dual inhibitor of the proteasome catalytic subunits LMP2 and Y attenuates disease progression in mouse models of Alzheimer's disease.一种蛋白酶体催化亚基 LMP2 和 Y 的双重抑制剂可减轻阿尔茨海默病小鼠模型中的疾病进展。
Sci Rep. 2019 Dec 5;9(1):18393. doi: 10.1038/s41598-019-54846-z.
8
Preclinical Development of -Based Botanical Lead IIIM-141 for Alzheimer's Disease: Chemical Standardization, Efficacy, Formulation Development, Pharmacokinetics, and Safety Pharmacology.基于植物提取物的阿尔茨海默病先导化合物IIIM-141的临床前开发:化学标准化、疗效、制剂开发、药代动力学和安全药理学。
ACS Omega. 2018 Aug 20;3(8):9572-9585. doi: 10.1021/acsomega.8b00841. eCollection 2018 Aug 31.
9
Tackling gaps in developing life-changing treatments for dementia.应对在开发改变痴呆症治疗方法方面存在的差距。
Alzheimers Dement (N Y). 2019 Jun 24;5:241-253. doi: 10.1016/j.trci.2019.05.001. eCollection 2019.
10
Amyloid β perturbs elevated heme flux induced with neuronal development.淀粉样蛋白β扰乱神经元发育诱导的血红素通量升高。
Alzheimers Dement (N Y). 2019 Jan 22;5:27-37. doi: 10.1016/j.trci.2018.12.003. eCollection 2019.
在结构化的五阶段开发框架背景下,延迟回忆测试作为阿尔茨海默病的一种前期生物标志物的临床有效性。
Neurobiol Aging. 2017 Apr;52:153-166. doi: 10.1016/j.neurobiolaging.2016.03.034.
4
Alzheimer's disease: time to focus on the brain, not just molecules.阿尔茨海默病:是时候关注大脑,而非仅仅关注分子了。
Brain. 2017 Feb;140(2):251-253. doi: 10.1093/brain/aww353.
5
Update on Alzheimer's Disease Therapy and Prevention Strategies.阿尔茨海默病治疗和预防策略的最新进展。
Annu Rev Med. 2017 Jan 14;68:413-430. doi: 10.1146/annurev-med-042915-103753.
6
The road to restoring neural circuits for the treatment of Alzheimer's disease.恢复神经回路以治疗阿尔茨海默病的道路。
Nature. 2016 Nov 10;539(7628):187-196. doi: 10.1038/nature20412.
7
Network abnormalities and interneuron dysfunction in Alzheimer disease.阿尔茨海默病中的网络异常与中间神经元功能障碍。
Nat Rev Neurosci. 2016 Dec;17(12):777-792. doi: 10.1038/nrn.2016.141. Epub 2016 Nov 10.
8
Drug development in Alzheimer's disease: the path to 2025.阿尔茨海默病的药物研发:通向2025年之路
Alzheimers Res Ther. 2016 Sep 20;8:39. doi: 10.1186/s13195-016-0207-9.
9
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.阿杜卡努单抗可减少阿尔茨海默病中的 Aβ 斑块。
Nature. 2016 Sep 1;537(7618):50-6. doi: 10.1038/nature19323.
10
The amyloid hypothesis of Alzheimer's disease at 25 years.阿尔茨海默病淀粉样蛋白假说25年回顾
EMBO Mol Med. 2016 Jun 1;8(6):595-608. doi: 10.15252/emmm.201606210. Print 2016 Jun.